Last reviewed · How we verify
NCT07109453
Dermatological Safety Assessment of Test Products Using Primary Irritation Patch Test (PIPT) in Healthy Adult Human Subjects
NA trial testing 18 Test Products along with positive and negative control in Normal in 26 participants. Not yet recruiting.
1 September 2025
Quick facts
| Lead sponsor | NovoBliss Research Pvt Ltd |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 26 |
| Start date | 25 August 2025 |
| Primary completion | 1 September 2025 |
| Estimated completion | 1 September 2025 |
Drugs / interventions tested
- 18 Test Products along with positive and negative control
Conditions studied
- Normal — all drugs for Normal →
- Sensitive Skin — all drugs for Sensitive Skin →
Sponsor
NovoBliss Research Pvt Ltd — full company profile →
Who can join
Adults 18 to 65, any sex, with Normal or Sensitive Skin. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
To evaluate the dermatological safety of the test products by 24 Hours Patch
Time frame: Irritation Scoring at T30 minutes and 24 hours post patch removal. Scoring can be done at T168 hours post-patch removal if needed
Test Dermatological safety of the test products by 24 Hours Patch Test will be evaluated by 0: No reaction and 4 Severe Reaction
Sponsor's own description
To Check Dermatological Safety of Test Products by 24 Hours Patch Testing
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07109453
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Normal
Currently open trials in the same condition.
- NCT07055152 — Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients · recruiting
Other NovoBliss Research Pvt Ltd trials
Trials by the same sponsor.
- NCT07466667 — To Determine the Effect of Phaseolean on Glycemic Response to Carbohydrate Rich Meal in Healthy Adult Human Participants · NA · not yet recruiting
- NCT07423325 — Validation of Skin Instrumentation to Detect Ceramide-Driven Lipid Replenishment - Assessing Skin Glow, Hydration, Trans · NA · not yet recruiting
- NCT07333300 — Exploratory Clinical Investigation on Neurosensory Responses Via EEG Headband in Adults With Mild to Moderate Atopic Der · NA · not yet recruiting
- NCT07324759 — Clinical Study to Assess Safety, Effectiveness and In-Use Tolerability of Saffron Extract Capsules for Improving Skin He · NA · not yet recruiting
- NCT07195487 — A Clinical Study to Evaluate the Safety, Effectiveness and In-Use Tolerability of Hair Growth and Scalp Health Serum in · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07109453 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NovoBliss Research Pvt Ltd
- Last refreshed: 7 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07109453.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing